证券日报网讯 12月2日，爱朋医疗在互动平台回答投资者提问时表示，公司布局了非侵入式脑机接口产 品ADHD行为治疗管理系统和顽固性失眠麻醉治疗系统。ADHD行为治疗和顽固性失眠治疗在院内均有 相应的收费目录。同时湖北、浙江、江苏等地相继出台脑机接口相关医疗服务价格项目，相关政策也将 推进脑机接口临床实践及应用提速。 （文章来源：证券日报） ...

格隆汇12月2日丨爱朋医疗(300753.SZ)在投资者互动平台表示，公司布局了非侵入式脑机接口产品 ADHD行为治疗管理系统和顽固性失眠麻醉治疗系统。ADHD行为治疗和顽固性失眠治疗在院内均有相 应的收费目录。同时湖北、浙江、江苏等地相继出台脑机接口相关医疗服务价格项目，相关政策也将推 进脑机接口临床实践及应用提速。 ...

Core Insights - Brain-computer interface (BCI) technology is seen as a revolutionary field that could enable paralyzed individuals to walk again, restore vision for the visually impaired, and treat various neurological diseases, offering hope to many patients [2][6] - Elon Musk predicts that within 20 years, Neuralink's technology could allow humans to create a "snapshot" of their minds and upload it to Tesla's humanoid robot, Optimus, potentially achieving a form of digital immortality [2] - The global BCI industry is rapidly developing, with major countries implementing policies to seize leadership in this emerging technology [3][6] Industry Development - The U.S. has introduced the "Neural Engineering System Design Program," Japan has launched the "Brain/Heart Function Utilization Technology Promotion Strategy," and the EU has initiated the "Human Brain Project" [3] - China is also prioritizing BCI development, with a national policy aiming for key technological breakthroughs by 2027 and the cultivation of 2-3 global leading companies by 2030 [6] - The BCI industry in China has established a comprehensive supply chain, with the medical field currently accounting for 56% of downstream applications [6][8] Clinical Progress - Clinical advancements are evident, with Shanghai Huashan Hospital completing its first BCI implantation surgery, and several products from Aipeng Medical already generating sales [8] - China has conducted 30 clinical trials for BCIs, surpassing Neuralink's 7 trials, indicating a competitive edge in clinical applications [8] Market Potential - The BCI technology is expected to create a trillion-dollar market, driving growth across materials, chips, and medical devices, and becoming a significant new productive force [8] - The global BCI market is projected to reach $7.63 billion by 2029, although predictions vary due to ethical and social acceptance challenges [9]

Core Viewpoint - Shanghai Ladder Medical Technology Co., Ltd. has announced that its self-developed "Implantable Wireless Brain-Computer Interface System" has officially entered the special review procedure for innovative medical devices by the National Medical Products Administration, marking a significant step in the industrialization of brain-computer interface technology in China [1][2]. Group 1: Product Development and Approval - The implantable brain-computer interface is the first invasive product to enter the "green channel" in China, which allows for accelerated review and approval processes, reduced registration fees, and comprehensive support for innovation [1][2]. - The product integrates key technologies for neural signal acquisition, decoding, and control, enabling precise motor signal recognition, which opens new avenues for functional replacement for patients with motor disabilities [2][6]. - The product must meet three core conditions to enter the "green channel": compliance with intellectual property rights, a standardized research process, and outstanding technical and clinical value [3]. Group 2: Market Potential and Growth - The brain-computer interface industry is transitioning from laboratory research to clinical and commercial stages, with the Chinese market projected to reach 3.2 billion yuan in 2024, growing at a rate of 18.8%, and expected to reach 6.14 billion yuan by 2028, with a compound annual growth rate of 17.7% [7]. - The implementation of policies to promote the innovation and development of the brain-computer interface industry is expected to enhance the industry's innovation capabilities and establish a reliable industrial system by 2030 [7][8]. - The recent approval of the first industry standard for brain-computer interface medical devices in China aims to unify terminology and provide a foundation for research, registration, and regulation [8]. Group 3: Industry Challenges and Dynamics - Despite the promising outlook, the transition from clinical research to commercial viability for brain-computer interfaces faces challenges such as technology maturity verification, collaborative development across the industry chain, and market awareness cultivation [8][9]. - Recent fluctuations in A-share brain-computer interface concept stocks indicate market volatility, with companies experiencing significant price changes following news related to the industry [8].

Core Insights - Aipeng Medical (300753.SZ) has multiple products in the brain-computer interface (BCI) field that have been commercialized, including an anesthetic depth monitor for perioperative brain state monitoring and a treatment system for refractory insomnia [1] - The company has a stake in Changzhou Ruishen'an Medical, which has received approval for its implanted deep brain stimulation device [1] - Currently, the company does not have any products applying for the special review process for innovative medical devices [1] Industry Developments - The first invasive brain-computer interface product, a "wireless implanted brain-computer interface system" developed by Shanghai Ladder Medical Technology Co., has entered the special review process of the National Medical Products Administration (NMPA), marking a significant step in the industrialization of this cutting-edge technology in China [3] - This development indicates a shift from clinical validation to market access for BCI products in China, highlighting the growing importance of this technology in the medical field [3]

每经AI快讯，有投资者在投资者互动平台提问：（五）丰富民生领域应用场景 医疗卫生领域。推动大 数据、物联网、脑机接口等新一代信息技术及医疗机器人等智能设备集成应用，创新健康咨询、问诊指 引、辅助诊断、远程医疗、用药审核等医疗应用场景。 养老助残托育领域。创新服务机器人、智能可 穿戴设备、远程终端服务系统、在线家庭医生药师等应用场景，打造科技助残、家政服务、托育照护、 康复医疗、健康服务等相结合的生活服务场景。 贵司在这方面有什么产品？ （记者 曾健辉） 爱朋医疗（300753.SZ）11月13日在投资者互动平台表示，您好，公司在医疗卫生领域积极推动新一代 信息技术的应用，尤其在脑机接口技术方面，公司推出了顽固性失眠麻醉治疗系统，该系统针对顽固性 失眠麻醉睡眠诊疗临床需求而设计；多模态ADHD行为训练系统，采用科学脑电监测、多模态干预训练 等方式，帮助儿童逐步改善多动及注意缺陷行为，提升专注力。在养老助残托育领域，公司通过参股常 州瑞神安，布局了脑神经调控及颅内植入电极等医疗器械产品的研发、生产及销售，包括一次性使用颅 内脑电极（SEEG）、植入式迷走神经刺激器（VNS）、植入式可充电脊髓刺激器（SCS）及植入 ...

Core Insights - Aipeng Medical announced the successful registration of its perioperative brain state monitoring product, the anesthesia depth monitor, which has received three registration certificates and has been launched in over 20 provinces, generating sales [2] - The company has introduced a new treatment system for refractory insomnia, which has begun clinical treatments in hospitals and is now being commercially promoted, with charges based on actual treatment projects [2] - Aipeng Medical has obtained registration certificates for two EEG collection products, which are core components of its "multimodal ADHD behavioral treatment management system," and has established a joint laboratory with Fudan University Children's Hospital to integrate research innovation with clinical applications for ADHD children [2] - The ADHD behavioral treatment has a corresponding fee schedule in hospitals, and regions like Hubei, Zhejiang, and Jiangsu have introduced pricing for non-invasive brain-computer interface services, with a fee of 966 yuan per session [2] - A new regulation from the National Healthcare Security Administration on September 24 has opened a "green channel" for insurance coding of innovative medical products like brain-computer interfaces, accelerating their clinical practice and application [2]

Core Insights - The company Aipeng Medical has received three registration certificates for its perioperative brain state monitoring product, the anesthesia depth monitor, and has completed network access in over 20 provinces, generating sales [1] - A new treatment system for refractory insomnia has been launched and is currently undergoing clinical treatment in hospitals, with commercialization efforts initiated based on actual treatment project execution [1] - The company has established a joint laboratory for brain-machine interface behavioral therapy in collaboration with the Children's Hospital affiliated with Fudan University, focusing on cognitive behavioral therapy for children with ADHD [1] - The core component of the multimodal ADHD behavioral management system has received registration certification, and non-invasive brain-machine interface adaptation fees have been set at 966 yuan per session in regions such as Hubei, Zhejiang, and Jiangsu [1] - The National Medical Insurance Administration has opened a "green channel" for innovative products like brain-machine interfaces, facilitating the acceleration of clinical application [1]

Group 1: Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and nasal airway management, while also exploring brain-computer interface innovations [4] - The company has established a partnership with Ruishen'an Medical, a leading player in the domestic neuroregulation field [4] Group 2: Product Development and Market Position - The company has launched a perioperative brain state monitoring product, which has received 3 registration certificates and is generating sales across over 20 provinces [5] - The newly introduced treatment system for refractory insomnia has begun clinical applications, with pricing based on specific treatment projects [5] - The non-invasive brain-computer interface adaptation fee is set at 966 RMB per session, with recent regulations facilitating insurance coverage for innovative medical products [5] Group 3: Technological Advancements - The anesthesia depth monitoring device utilizes a proprietary index, collecting EEG data at 2,000 times per second, providing a comprehensive analysis of anesthesia depth [8] - The company’s new generation ADM series anesthesia depth monitor offers enhanced performance, usability, and stability, with features including EEG spectrum analysis and anesthesia depth assessment [8] Group 4: Strategic Collaborations - Aipeng Medical's investment in Ruishen'an in 2019 was driven by strategic synergies in chronic pain treatment, particularly with the development of implantable vagus nerve stimulators [9][10] - The collaboration has expanded to include various products for epilepsy and pain management, achieving significant sales [10] Group 5: Future Research and Development Plans - The company aims to deepen research in sensors, electrodes, and EEG signal processing, focusing on clinical applications for sleep disorders, ADHD, and epilepsy [11] - An Artificial Intelligence and Brain-Computer Engineering Research Institute has been established to drive innovation in pain management, anesthesia, and mental health treatment [11]

Core Insights - Jiangsu Aipeng Medical Technology Co., Ltd. conducted a conference call with 13 institutions, including Cinda Securities and Southern Fund, to discuss its business and future strategies [1] Company Overview - Aipeng Medical focuses on medical devices, particularly in chronic pain management and upper airway management, while also expanding into brain-computer interface (BCI) innovations [1] - The company's BCI applications include perioperative brain state monitoring, treatment systems for refractory insomnia, and multi-modal ADHD behavior management systems [1] Product Development - In the non-invasive sector, Aipeng has developed a multi-modal ADHD behavior management system that connects data from hospital to home, utilizing scientific EEG monitoring and multi-modal interventions [2] - The company has launched an anesthesia treatment system for refractory insomnia and is in the preliminary research phase for an epilepsy warning platform [2] - Aipeng has established a partnership with Changzhou Ruishen'an, focusing on the development and production of neuro-regulation and intracranial electrode medical devices [2] Market Expansion - Hospitals in provinces such as Hubei, Zhejiang, and Guangdong have announced pricing for BCI medical services, facilitating clinical application [2] - The new generation ADM series anesthesia depth monitoring device has received three registration certificates and is now available for sale in over 20 provinces [2] - The refractory insomnia anesthesia treatment system has been implemented in hospitals for clinical treatment and promotion [2] Consumer Product Strategy - The refractory insomnia anesthesia treatment system and multi-modal ADHD behavior management system target both hospital and consumer markets [2] - The multi-modal ADHD behavior training products include UMind (hospital version) and SE (home version), initially promoted in serious medical settings before expanding to consumer markets [2] Data Infrastructure - The refractory insomnia anesthesia treatment system is designed to meet clinical needs, incorporating smart interaction between doctors and patients, and tracking clinical data [2] - The multi-modal ADHD behavior training system integrates multi-source data collection and analysis, collaborating with Fudan University Children's Hospital to enhance data infrastructure and clinical application [2] Research and Development - Aipeng is building a BCI technology application platform to advance clinical innovations in mental health diagnosis and treatment [2] - The company aims to enhance its R&D capabilities and strengthen collaborations with renowned universities and research institutions to promote technological innovation and industry integration [2]